Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone

被引:28
作者
Jeremic, B
Shibamoto, Y
Milicic, B
Dagovic, A
Nikolic, N
Aleksandrovic, J
Acimovic, L
Milisavljevic, S
机构
[1] Univ Hosp, Kragujevac, Serbia
[2] Nagoya City Univ, Grad Sch Med Sci, Dept Radiol, Nagoya, Aichi, Japan
关键词
early stage; non-small-cell lung cancer; hyperfractionation; treatment interruption; toxicity;
D O I
10.1016/S0169-5002(03)00078-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated the effect of treatment interruptions due to high-grade (greater than or equal to3) toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer treated with hyperfractionated radiation therapy (Hfx RT). Of 116 patients treated with total tumour doses of 69.6 Gy, 1.2 Gy b.i.d. fractionation, 44 patients refused surgery while 72 patients were medically inoperable due to existing co-morbid states. Patients who were medically inoperable had worse KPS (P = 0.0059) and more pronounced weight loss (P = 0.0005). Among them, 12 patients experienced high-grade toxicity and 11 of them with either acute (n = 6) or 'consequential' late (it = 5) high-grade toxicity requested interruption in the Hfx RT course (range, 12-25 days; median, 17 days). Superior survival (OS) was observed in patients who refused surgery when compared to those who were medically inoperable (P = 0.0041), as well as superior local recurrence-free survival (LRFS) (P = 0.011), but not different distant metastasis-free survival (P = 0.14). Cause-specific survival (CSS) also favoured patients who refused surgery (P = 0.004). Multivariate analysis showed independent influence of the reason for not undergoing surgery on OS (P = 0.035), but not on LRFS (P = 0.084) or CSS (P = 0.068). Patients who refused surgery did not experience high-grade toxicity (0/44), whereas I I of 72 patients with medical inoperability and co-morbid states experienced high-grade toxicity and had treatment interruptions to manage toxicity (P = 0.0064). Patients without treatment interruptions had significantly better OS (P = 0.00000), LRFS (P = 0.00000) and CSS (P = 0.00000) than those with treatment interruptions. When corrected for treatment interruptions, the reason for not undergoing surgery independently influenced OS (P = 0.040), but not LRFS (P = 0.092) or CSS (P = 0.068). In contrast to this, treatment interruption was independent prognosticator of all three endpoints used (P = 0.00031, P = 0.0075 and P = 0.00033, respectively). When I I patients with treatment interruptions were excluded, the reason for not undergoing surgery still affected OS (P = 0.037) and CSS (P = 0.039) but not LRFS (P = 0.11). Multivariate analyses using OS, CSS and LRFS showed that the reason for not undergoing surgery affected OS (P = 0.0436), but neither CSS (P = 0.083) nor LRFS (P = 0.080). (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:317 / 323
页数:7
相关论文
共 34 条
[1]   A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable nonsmall cell lung cancer: final report of an Australian multi-centre trial [J].
Ball, D ;
Bishop, J ;
Smith, J ;
O'Brien, P ;
Davis, S ;
Ryan, G ;
Olver, I ;
Toner, G ;
Walker, Q ;
Joseph, D .
RADIOTHERAPY AND ONCOLOGY, 1999, 52 (02) :129-136
[2]   Updated data for chart in NSCLC: Further analyses [J].
Bentzen, SM ;
Saunders, MI ;
Dische, S ;
Parmar, MK .
RADIOTHERAPY AND ONCOLOGY, 2000, 55 (01) :86-87
[3]   The impact of overall treatment time on outcomes in radiation therapy for non-small cell lung cancer [J].
Chen, M ;
Jiang, GL ;
Fu, XL ;
Wang, LJ ;
Qian, H ;
Chen, GY ;
Zhao, S ;
Liu, TF .
LUNG CANCER, 2000, 28 (01) :11-19
[4]   Involved-field radiotherapy alone for early-stage non-small-cell lung cancer [J].
Cheung, PCF ;
Mackillop, WJ ;
Dixon, P ;
Brundage, MD ;
Youssef, YM ;
Zhou, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (03) :703-710
[5]   TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) [J].
COX, JD ;
STETZ, J ;
PAJAK, TF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05) :1341-1346
[6]  
COX JD, 1992, CANCER, V69, P2744, DOI 10.1002/1097-0142(19920601)69:11<2744::AID-CNCR2820691119>3.0.CO
[7]  
2-U
[8]   INTERRUPTIONS OF HIGH-DOSE RADIATION-THERAPY DECREASE LONG-TERM SURVIVAL OF FAVORABLE PATIENTS WITH UNRESECTABLE NONSMALL CELL-CARCINOMA OF THE LUNG - ANALYSIS OF 1244 CASES FROM 3 RADIATION-THERAPY ONCOLOGY GROUP (RTOG) TRIALS [J].
COX, JD ;
PAJAK, TF ;
ASBELL, S ;
RUSSELL, AH ;
PEDERSON, J ;
BYHARDT, RW ;
EMAMI, B ;
ROACH, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 27 (03) :493-498
[9]   RADIATION-THERAPY IN THE MANAGEMENT OF MEDICALLY INOPERABLE CARCINOMA OF THE LUNG - RESULTS AND IMPLICATIONS FOR FUTURE TREATMENT STRATEGIES [J].
DOSORETZ, DE ;
KATIN, MJ ;
BLITZER, PH ;
RUBENSTEIN, JH ;
SALENIUS, S ;
RASHID, M ;
DOSANI, RA ;
MESTAS, G ;
SIEGEL, AD ;
CHADHA, TT ;
CHANDRAHASA, T ;
HANNAN, SE ;
BHAT, SB ;
METKE, MP .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 24 (01) :3-9
[10]   LOSS OF LOCAL-CONTROL WITH PROLONGATION IN RADIOTHERAPY [J].
FOWLER, JF ;
LINDSTROM, MJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 23 (02) :457-467